1. Home
  2. GTLB vs GRFS Comparison

GTLB vs GRFS Comparison

Compare GTLB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GitLab Inc.

GTLB

GitLab Inc.

HOLD

Current Price

$34.28

Market Cap

6.0B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.87

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTLB
GRFS
Founded
2011
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.2B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
GTLB
GRFS
Price
$34.28
$8.87
Analyst Decision
Buy
Hold
Analyst Count
27
2
Target Price
$51.62
$10.15
AVG Volume (30 Days)
4.1M
485.7K
Earning Date
03-02-2026
07-28-2022
Dividend Yield
N/A
1.60%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
$906,253,000.00
$8,821,017,248.00
Revenue This Year
$27.21
$5.36
Revenue Next Year
$19.06
$5.15
P/E Ratio
N/A
$17.46
Revenue Growth
27.36
7.31
52 Week Low
$33.92
$6.19
52 Week High
$74.18
$11.14

Technical Indicators

Market Signals
Indicator
GTLB
GRFS
Relative Strength Index (RSI) 31.46 44.66
Support Level $34.04 $8.79
Resistance Level $36.73 $9.40
Average True Range (ATR) 1.30 0.24
MACD -0.05 -0.05
Stochastic Oscillator 6.34 12.18

Price Performance

Historical Comparison
GTLB
GRFS

About GTLB GitLab Inc.

GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: